Document Detail

Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results.
MedLine Citation:
PMID:  16355035     Owner:  NLM     Status:  MEDLINE    
OBJECTIVES: We sought to investigate whether thalidomide is able to produce tumor vascular changes in patients with untreatable hepatocellular carcinoma (HCC) that can be detected using microbubble contrast agents. MATERIALS AND METHODS: Eleven consecutive patients with untreatable HCC underwent contrast-enhanced ultrasound before and during thalidomide administration. Real-time destruction reperfusion kinetics was obtained from a representative HCC nodule and from the surrounding liver parenchyma during SonoVue infusion (Bracco, Milan, Italy) at a constant rate of 0.10 mL/s by using a syringe pump and modelized according to the mathematical function SI = A(1 - exp(-betat)) where the plateau signal intensity A reflects the percent blood volume, the time constant beta reflects the average speed of blood, and their product A*beta reflects the nutrient blood flow. RESULTS: Size of the representative nodule reduced significantly 3 to 6 months after the start of thalidomide treatment. Before thalidomide administration A, beta, and A*beta of the index lesion were 44 +/- 60 LIU, 0.31 +/- 0.40 seconds and 8.1 +/- 11.8 LIU/s, respectively). A and A*beta reduced significantly after 15 days (26 +/- 50 LIU and 2.9 +/- 4.8 LIU/s, P < 0.01), 3 months (12 +/- 18 LIU, and 4.3 +/- 7.7 LIU/s, P < 0.01), and 6 months (13 +/- 23 LIU and 2.4 +/- 3.7 LIU/s, P < 0.05) of treatment. No statistically significant changes of the exponential time constant beta were observed, nor changes of A, beta and A*beta in the liver parenchyma. CONCLUSIONS: Contrast-enhanced ultrasound can be used effectively to evaluate changes in perfusion parameters of HCC nodules during thalidomide administration.
Michele Bertolotto; Gabriele Pozzato; Lory Saveria Crocè; Fabiana Nascimben; Cristiana Gasparini; Maria Assunta Cova; Claudio Tiribelli
Related Documents :
13495 - Mode of action of beta blockers in angina pectoris.
1350235 - The hemodynamic effects of adrenergic blocking agents.
6147255 - Pafenolol, a new beta 1-selective blocking agent, in mild hypertension. result of an in...
631185 - Analysis of the vasodilator action of alprenolol.
19789855 - Lung recruitment assessed by total respiratory system input reactance.
8406655 - Feasibility and efficacy of sodium reduction in the trials of hypertension prevention, ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Investigative radiology     Volume:  41     ISSN:  0020-9996     ISO Abbreviation:  Invest Radiol     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-15     Completed Date:  2006-03-23     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0045377     Medline TA:  Invest Radiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  15-21     Citation Subset:  IM    
UCO di Radiologia, Università di Trieste, Ospedale di Cattinara, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use*
Carcinoma, Hepatocellular / drug therapy*,  ultrasonography
Contrast Media
Image Processing, Computer-Assisted
Liver Neoplasms / drug therapy*,  ultrasonography
Middle Aged
Neovascularization, Pathologic / drug therapy*
Phospholipids / diagnostic use
Statistics, Nonparametric
Sulfur Hexafluoride / diagnostic use
Survival Analysis
Thalidomide / therapeutic use*
Treatment Outcome
Ultrasonography, Interventional*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Contrast Media; 0/Phospholipids; 0/contrast agent BR1; 2551-62-4/Sulfur Hexafluoride; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial distribution of calibrated tris-acryl gelatin and polyvinyl alcohol microspheres in a sheep...
Next Document:  64- Versus 16-slice CT angiography for coronary artery stent assessment: in vitro experience.